Novartis: positive data for breast cancer drug

(CercleFinance.com) - Novartis reports positive primary endpoint data for its Kisqali in the pivotal Phase III NATALEE trial at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.


The Swiss healthcare group says its product significantly reduced the risk of recurrence by 25% in a large population of patients with early stage breast cancer, with a consistent clinically significant benefit in all subgroups.

Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend towards improved overall survival, Novartis adds.


Copyright (c) 2023 CercleFinance.com. All rights reserved.